Effect of gastric bypass surgery on the incretins

Diabetes and Metabolism

Volumn 35, Issue 6 PART II, 2009, Pages 513-517

  Laferrere B ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Diabetes; gastric bypass; GIP; GLP 1; Incretin effect; Review

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN;

APPETITE; ARTICLE; BODY MASS; DIET; ENERGY BALANCE; HUMAN; INSULIN RELEASE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; STOMACH BYPASS; WEIGHT REDUCTION;

EID: 75249083518     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(09)73458-5     Document Type: Article

References (43)

1. Buchwald H., Avidor Y., Braunwald E., Jensen M.D., Pories W., Fahrbach K., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
2. Dixon J.B., O'Brien P.E., Playfair J., Chapman L., Schachter L.M., Skinner S., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299 (2008) 316-323
3. Rossetti L., Giaccari A., and DeFronzo R.A. Glucose toxicity. Diabetes Care 13 (1990) 610-630
4. Leahy J.L., Bonner-Weir S., and Weir G.C. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 15 (1992) 442-455
5. Laferrère B., Heshka S., Wang K., Khan Y., McGinty J., Teixeira J., et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30 (2007) 1709-1716
6. Laferrère B., Teixeira J., McGinty J., Tran H., Egger J.R., Colarusso A., et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93 (2008) 2479-2485
7. Kreymann B., Williams G., Ghatei M.A., and Bloom S.R. Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet 2 (1987) 1300-1304
8. Holst J.J., and Orskov C. Incretin hormones--an update. Scand J Clin Lab Invest Suppl 61 suppl 234 (2001) 75-85
9. Theodorakis M.J., Carlson O., Michopoulos S., Doyle M.E., Juhaszova M., Petraki K., et al. Human duodenal enteroendocrine cells: source of both incretin peptides. GLP-1 and GIP. Am J Physiol Endocrinol Metab 290 (2006) E550-E559
10. Ebert R., and Creutzfeldt W. Gastrointestinal peptides and insulin secretion. Diabetes Metab Rev 3 (1987) 1-26
11. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63 (1986) 492-498
12. Vilsboll T., Krarup T., Madsbad S., and Holst J. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regulatory Peptides 114 (2003) 115-121
13. Preitner F., Ibberson M., Franklin I., Binnert C., Pende M., Gjinovci A., et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 113 (2004) 635-645
14. Creutzfeldt W. The incretin concept today. Diabetologia 16 (1979) 75-85
15. Flint A., Raben A., Ersboll A.K., Holst J.J., and Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25 (2001) 781-792
16. Gutzwiller J.P., Drewe J., Goke B., Schmidt H., Rohrer B., Lareida J., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276 5 Pt 2 (1999) R1541-R1544
17. Naslund E., Bogefors J., Skogar S., Gryback P., Jacobsson H., Holst J.J., et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277 3 Pt 2 (1999) R910-R916
18. D'Alessio D.A., Prigeon R.L., and Ensinck J.W. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 44 (1995) 1433-1437
19. Nauck M., Stockmann F., Ebert R., and Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986) 46-52
20. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 49 (2006) 253-260
21. Sarson D.L., Scopinaro N., and Bloom S.R. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 5 (1981) 471-480
22. Naslund E., Gryback P., Hellstrom P.M., Jacobsson H., Holst J.J., Theodorsson E., et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21 (1997) 387-392
23. Naslund E., Backman L., Holst J.J., Theodorsson E., and Hellstrom P.M. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 8 (1998) 253-260
24. Morinigo R., Moize V., Musri M., Lacy A.M., Navarro S., Marin J.L., et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91 (2006) 1735-1740
25. Sarson D.L., Besterman H.S., and Bloom S.R. Radioimmunoassay of gastric inhibitory polypeptide and its release in morbid obesity and after jejuno-ileal bypass [proceedings]. J Endocrinol 81 (1979) 155P-156P
26. Lauritsen K.B., Christensen K.C., and Stokholm K.H. Gastric inhibitory polypeptide (GIP) release and incretin effect after oral glucose in obesity and after jejunoileal bypass. Scand J Gastroenterol 15 (1980) 489-495
27. Halverson J.D., Kramer J., Cave A., Permutt A., and Santiago J. Altered glucose tolerance, insulin response, and insulin sensitivity after massive weight reduction subsequent to gastric bypass. Surgery 92 (1982) 235-240
28. Kindel T.L., Yoder S.M., Seeley R.J., D'Alessio D.A., and Tso P. Duodenal-Jejunal Exclusion Improves Glucose Tolerance in the Diabetic. Goto-Kakizaki Rat by a GLP-1 Receptor-Mediated Mechanism. J Gastrointest Surg 13 (2009) 1762-1772
29. Verdich C., Toubro S., Buemann B., Lysgard M.J., Juul H.J., and Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25 (2001) 1206-1214
30. Cohen R.V., Schiavon C.A., Pinheiro J.S., Correa J.L., and Rubino F. Duodenaljejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases. Surg Obes Relat Dis 3 (2007) 195-197
31. Naslund E., Backman L., Holst J.J., Theodorsson E., and Hellstrom P.M. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 8 (1998) 253-260
32. Service G.J., Thompson G.B., Service F.J., Andrews J.C., Collazo-Clavell M.L., and Lloyd R.V. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 353 (2005) 249-254
33. Cummings D.E. Gastric bypass and nesidioblastosis--too much of a good thing for islets?. N Engl J Med 353 (2005) 300-302
34. Kellogg T.A., Bantle J.P., Leslie D.B., Redmond J.B., Slusarek B., Swan T., et al. Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. Surg Obes Relat Dis 4 (2008) 492-499
35. Farilla L., Bulotta A., Hirshberg B., Li C.S., Khoury N., Noushmehr H., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 (2003) 5149-5158
36. Cornu M., Yang J.Y., Jaccard E., Poussin C., Widmann C., and Thorens B. Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop. Diabetes 58 (2009) 1816-1825
37. Rubino F., and Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239 (2004) 1-11
38. Pacheco D., de Luis D.A., Romero A., Gonzalez S.M., Conde R., Izaola O., et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg 194 (2007) 221-224
39. Patriti A., Facchiano E., Annetti C., Aisa M.C., Galli F., Fanelli C., et al. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg 15 (2005) 1258-1264
40. Strader A.D., Vahl T.P., Jandacek R.J., Woods S.C., D'Alessio D.A., and Seeley R.J. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 288 (2005) E447-E453
41. Strader A.D. Ileal transposition provides insight into the effectiveness of gastric bypass surgery. Physiol Behav 88 (2006) 277-282
42. Horowitz M., Collins P.J., Harding P.E., and Shearman D.J. Gastric emptying after gastric bypass. Int J Obes 10 (1986) 117-121
43. Rubino F., Forgione A., Cummings D.E., Vix M., Gnuli D., Mingrone G., et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244 (2006) 741-749